Literature DB >> 6678966

Concentration of vinblastine in human intracerebral tumor and other tissues.

D J Stewart, K Lu, R S Benjamin, M E Leavens, M Luna, H Y Yap, T L Loo.   

Abstract

Uptake of vinblastine into human cerebrospinal fluid, intracerebral tumor and autopsy tissues was quantitated radiochemically after separating vinblastine from its metabolites by high pressure liquid chromatography. Only low concentrations of vinblastine were found in cerebrospinal fluid from a single patient. A second patient who received a tracer dose of radiolabelled vinblastine prior to surgical resection of an intracerebral tumor had slightly less radioactivity in tumor than in temporalis muscle, but more in tumor than in edematous brain surrounding the tumor. The radioactivity in tumor increased gradually and exceeded concurrent plasma radioactivity by 2 hr after drug administration. A third patient died 4 hr into a planned 24-hr infusion of radiolabeled vinblastine. Highest vinblastine concentrations were found in organs with high blood flow such as kidney and heart. Intermediate concentrations were found in liver and lung, and low concentrations were found in prostate, gastrointestinal tract, spleen, muscle, bladder, and hepatic and lymph node metastases. A fourth patient died one month after receiving radiolabeled vinblastine. Highest concentrations were in liver and next highest concentrations were in intracerebral tumor. Moderately high concentrations were found in pancreas, thyroid, lung, spleen, ovary, kidney, and kidney metastases. Lowest concentrations were found in omental metastases, heart, breast, and brain. Vinblastine concentration decreased with increasing distance into brain from the brain metastases. Thus, vinblastine was not selectively localized in tumors. The concentrations in tumor did not reflect the concentration in the organ in which the tumor was located. There was no indication that uptake into intracerebral tumor was impaired. Cerebrospinal fluid and brain concentrations of vinblastine did not give any indication of the concentration attainable in intracerebral tumor.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6678966     DOI: 10.1007/bf00182959

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  12 in total

1.  Correlation of biologic data with physico-chemical properties among the vinca alkaloids and their congeners.

Authors:  R J Owellen; D W Donigian; C A Hartke; F O Hains
Journal:  Biochem Pharmacol       Date:  1977-07-01       Impact factor: 5.858

2.  An electric analogue for uptake and exchange of inert gases and other agents.

Authors:  W W MAPLESON
Journal:  J Appl Physiol       Date:  1963-01       Impact factor: 3.531

3.  Pharmacokinetics and metabolism of vinblastine in humans.

Authors:  R J Owellen; C A Hartke; F O Hains
Journal:  Cancer Res       Date:  1977-08       Impact factor: 12.701

4.  Studies on the binding of ( 3 H)vinblastine by rat blood platelets in vitro. Effects of colchicine and vincristine.

Authors:  C J Secret; J R Hadfield; C T Beer
Journal:  Biochem Pharmacol       Date:  1972-06-01       Impact factor: 5.858

Review 5.  A pharmacologic basis for brain tumor chemotherapy.

Authors:  V A Levin
Journal:  Semin Oncol       Date:  1975-03       Impact factor: 4.929

6.  Human central nervous system distribution of cis-diamminedichloroplatinum and use as a radiosensitizer in malignant brain tumors.

Authors:  D J Stewart; M Leavens; M Maor; L Feun; M Luna; J Bonura; R Caprioli; T L Loo; R S Benjamin
Journal:  Cancer Res       Date:  1982-06       Impact factor: 12.701

7.  Permeability characteristics of brain adjacent to tumors in rats.

Authors:  V A Levin; M Freeman-Dove; H D Landahl
Journal:  Arch Neurol       Date:  1975-12

8.  Penetration of methylglyoxal bis(guanylhydrazone) into intracerebral tumors in humans.

Authors:  M G Rosenblum; D J Stewart; B S Yap; M Leavens; R S Benjamin; T L Loo
Journal:  Cancer Res       Date:  1981-02       Impact factor: 12.701

9.  Penetration of 3-deazauridine into human brain, intracerebral tumor, and cerebrospinal fluid.

Authors:  D J Stewart; J A Benvenuto; M Leavens; S W Hall; R S Benjamin; W Plunkett; K B McCredie; M A Burgess; T L Loo
Journal:  Cancer Res       Date:  1979-10       Impact factor: 12.701

10.  Pharmacokinetics of vincristine in the cerebrospinal fluid of humans.

Authors:  D V Jackson; V S Sethi; C L Spurr; J M McWhorter
Journal:  Cancer Res       Date:  1981-04       Impact factor: 12.701

View more
  25 in total

Review 1.  Do anticancer agents reach the tumor target in the human brain?

Authors:  M G Donelli; M Zucchetti; M D'Incalci
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 2.  Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain.

Authors:  Sagar Agarwal; Ramola Sane; Rajneet Oberoi; John R Ohlfest; William F Elmquist
Journal:  Expert Rev Mol Med       Date:  2011-05-13       Impact factor: 5.600

Review 3.  A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors.

Authors:  D J Stewart
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

Review 4.  The role of chemotherapy in the treatment of patients with brain metastases from solid tumors.

Authors:  J C Buckner
Journal:  Cancer Metastasis Rev       Date:  1991-12       Impact factor: 9.264

5.  Cisplatin plus cytosine arabinoside in adults with malignant gliomas.

Authors:  D J Stewart; M T Richard; B Benoit; H Hugenholtz; N Russell; J Dennery; E Peterson; Z Grahovac; G Belanger; S Aitkens
Journal:  J Neurooncol       Date:  1984       Impact factor: 4.130

6.  Factors affecting human autopsy kidney-cortex and kidney-medulla platinum concentrations after cisplatin administration.

Authors:  D J Stewart; C Dulberg; J M Molepo; N Z Mikhael; V A Montpetit; M D Redmond; R Goel
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

7.  Penetration of teniposide (VM-26) into human intracerebral tumors. Preliminary observations on the effect of tumor type, rate of drug infusion and prior treatment with amphotericin B or oral glycerol.

Authors:  D J Stewart; M T Richard; H Hugenholtz; J Dennery; D Nundy; J Prior; V Montpetit; H S Hopkins
Journal:  J Neurooncol       Date:  1984       Impact factor: 4.130

Review 8.  The Treatment of Melanoma Brain Metastases.

Authors:  Nour Kibbi; Harriet Kluger
Journal:  Curr Oncol Rep       Date:  2016-12       Impact factor: 5.075

9.  Human autopsy tissue distribution of the epipodophyllotoxins etoposide and teniposide.

Authors:  D J Stewart; D Grewaal; M D Redmond; N Z Mikhael; V A Montpetit; R Goel; R M Green
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

10.  Human autopsy-tissue distribution of menogaril and its metabolites.

Authors:  D J Stewart; D Grewaal; R M Green; R Goel; N Mikhael; V A Montpetit; D Redmond; R Earhart
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.